Investor relations

Biocompatibles is committed to delivering shareholder value by:

  • developing and commercialising a range of products to treat various
    cancer indications so as to improve the survival chances and quality of
    life of cancer patients
  • developing products for growing markets and adhering to aggressive
    timelines
  • responsibly managing the Company's financial resources

Following the sales of the contact lens and cardiovascular stent businesses in 2002, Biocompatibles has returned £123m of capital to shareholders.

Presentations


Advanced Search

 

© 2009 Biocompatibles UK Ltd - All rights reserved - Site map - Terms & conditions - Accessiblity - Help - Glossary